What Has These Insiders Excited About Their Companies’ Stock?

Investors have been monitoring insider trading activity for years, as corporate insiders surely have more in-depth knowledge about their companies’ operations and industries than an average investor. Of course, they are not allowed to trade based on material non-public information, but this does not necessarily mean that they do not have their own perception about their companies’ future prospects. Typically, investors tend to pay more attention to insider buying rather than insider selling, as the former type of activity is quite straightforward to interpret. Extensive research has provided evidence that insider purchases are profitable and non-insiders can outperform the broader market by mimicking insiders’ moves. However, one should not blindly follow each insider buy and expect to generate exorbitant returns; insiders are also prone to making mistakes on some occasions. Each insider trade should be closely analyzed and accurately interpreted in order to eliminate potential losing trades from great buying opportunities. The Insider Monkey team pinpointed three companies that have registered heavy insider buying since the beginning of the current trading week and this article will attempt to stipulate what might have propelled these companies’ insiders to purchase stock.

stocks, analysis, market, numbers, business, ticket, trade, money, price

photofriday/Shutterstock.com

Most investors can’t outperform the stock market by individually picking stocks because stock returns aren’t evenly distributed. A randomly picked stock has only a 35%-to-45% chance (depending on the investment horizon) to outperform the market. There are a few exceptions, one of which is when it comes to purchases made by corporate insiders. Academic research has shown that certain insider purchases historically outperformed the market by an average of seven percentage points per year. This effect is more pronounced in small-cap stocks. Another exception is the small-cap stock picks of hedge funds. Our research has shown that the 15 most popular small-cap stocks among hedge funds outperformed the market by nearly a percentage point per month between 1999 and 2012. We have been forward testing the performance of these stock picks since the end of August 2012 and they have returned more than 102% over the ensuing three-plus years, outperforming the S&P 500 Index by more than 53 percentage points (read the details here). The trick is focusing only on the best small-cap stock picks of funds, not their large-cap stock picks which are extensively covered by analysts and followed by almost everybody.

Let’s begin our discussion with Las Vegas Sands Corp. (NYSE:LVS), which has recently seen an insider buy stock for the first time in more than five years. Director Steven L. Gerard purchased 1,000 shares on Wednesday at a price of $47.95 per share. The Director currently owns a stake of 2,818 shares valued at nearly $138,000. Despite facing a challenging operating environment in Macau, especially in the high-end gaming segment, the casino operator performed quite well during the third quarter. Las Vegas Sands Corp. (NYSE:LVS) reported third quarter adjusted earnings per share of $0.66, compared to EPS of $0.84 reported a year ago and $0.64 anticipated by analysts. However, the company posted net revenue of $2.89 billion, which decreased by 18.1% year-over-year and missed analysts’ expectations by $80 million. The stock is currently trading at a forward P/E ratio of 18.96, slightly above the ratio of 18.5 for the casinos and gaming sector. Murray Stahl’s Horizon Asset Management owned approximately 749,000 shares of Las Vegas Sands Corp. (NYSE:LVS) at the end of June.

Follow Las Vegas Sands Corp (NYSE:LVS)

The next page of the article discusses the insider buying activity at Stepan Company (NYSE:SCL) and Cempra Inc. (NASDAQ:CEMP).

Moving on to Stepan Company (NYSE:SCL), Director Jan Stern Reed acquired a 1,000-share stake on Tuesday at a price of $51.21 per unit. Just recently, the manufacturer of specialty and intermediate chemicals released strong third quarter financial results. Although the U.S dollar acted as a drag on the company’s bottom-line, Stepan Company (NYSE:SCL)’s net income increased by 85% year-over-year to $24.9 million or $1.09 per diluted share. Specifically, the foreign currency translation affected the net income figure by $2.8 million or $0.12 per share. In the meantime, the company’s net sales decreased by 10% year-over-year to $444.01 million, mainly owing to lower selling prices and the impact of currency exchange rates. Even so, the volume of sales increased by 7% compared to the same quarter last year. The stock is 33% in the green year-to-date, but its forward P/E ratio of 14.59 might suggest that the stock has more room to run in the months ahead. Let’s also not forget to mention that Stepan Company announced a 5.6% increase to its quarterly cash dividend, to $0.19 per share. David Dreman’s Dreman Value Management added a 128,000-share position in Stepan Company (NYSE:SCL) to its portfolio during the June quarter.

Follow Stepan Co (NYSE:SCL)

Finally, we will investigate the insider buying activity at clinical-stage pharmaceutical company Cempra Inc. (NASDAQ:CEMP). Director Michael R. Dougherty purchased a new 2,000-share block on Monday for $18.45 each. Garheng Kong, another member of the company’s Board of Directors, also bought a new stake of 2,830 shares at a weighted average price of $17.42. The shares of the company have been on a downfall since late July, losing 62% from July 31 through October 22, when the pharmaceutical company released its third quarter financial results and corporate update. The stock has bounced back by 51% since then and is slightly over 1% in the green year-to-date. Although there was nothing about Cempra Inc. (NASDAQ:CEMP)’s financial results that would encourage investors to regain confidence in the company, it appears that its clinical development highlights have reassured long-term investors that the company is set to reach its long-term goals. Dennis Purcell’s Aisling Capital was the largest shareholder of Cempra Inc. (NASDAQ:CEMP) within our database at the end of the second quarter, holding 2.19 million shares.

Follow Melinta Therapeutics Inc. W (NASDAQ:MLNT)

Disclosure: None